Prostate cancer is the cancer that occurs in the male's prostate.
It is the most common cancer in men >50 years of age.
Signs and symptoms include weak urinary stream, polyuria, nocturia, hematuria, erectile dysfunction, pelvic pain, back pain, chest pain, lower extremity weakness or numbness and loss of bowel or bladder control.
Patients with a positive post-treatment biopsy after external beam radiotherapy are at higher risk of distant metastasis and prostate cancer-related death, suggests a recent study. Positive post-treatment biopsies are more frequent in the setting of external beam radiotherapy alone without androgen deprivation therapy or in the presence of high-risk disease.
Men with advanced prostate cancer who have pre-existing cardiovascular disease (CVD) may have an elevated mortality risk after treatment with abiraterone acetate compared with men who do not have CVD, according to a study presented at AACR 2019.
Decision making in men with newly diagnosed favourable-risk prostate cancer is driven by magnetic resonance imaging (MRI) and post-MRI biopsy, according to a study, noting that post-MRI biopsy is a stronger driver of decision making than MRI alone.
Men with nonmetastatic castration-resistant prostate cancer (nmCRPC) more than halved their risk of dying or developing distant metastasis when treated with darolutamide in addition to androgen deprivation therapy (ADT), according to findings of the phase III ARAMIS* trial.
Detection of overall and index prostate cancer is comparable in three Tesla multiparametric magnetic resonance imaging (MRI) with and without an endorectal coil, a study has found. However, the endorectal coil subcohort has markedly higher detection of posterior and peripheral prostate cancer, as well as detection of anterior and transition zone prostate cancer.
Radical prostatectomy can provide long-term survival benefits and reduce the risk of distant metastasis in otherwise healthy men with clinically detected, localized prostate cancer, according to findings from 23 years of follow-up of the SPCG-4 study (Scandinavian Prostate Cancer Group Study Number 4).
Stereotactic body radiotherapy (SBRT) is associated with significantly lower rates of acute gastrointestinal (GI) and genitourinary (GU) toxicities compared with conventional fractionated intensity-modulated radiotherapy (CF-IMRT) in Asian patients with early-stage localized prostate cancer.
External beam radiation therapy is a standard option for the initial management of men with localized prostate cancer, and a new guideline states that hypofractionation of radiation treatment confers benefits for cost and convenience.
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.